showed that both Illumina and BGI mNGS platforms outperformed conventional methods in sensitivity, with negligible differences between each platform. This implies that mNGS can enhance pulmonary infection diagnosis by providing earlier pathogen identification, honing treatment precision, and enriching epidemiological insights. The rising incidence and mortality of fungal infections, including pulmonary mycosis, underscore the urgency for the demand of precise diagnosis and efficient treatment (9). Bronchoscopic instillation has been hailed as a novel therapeutic approach for pulmonary mycosis, offering precise local targeting of lesions.However, there has been a lack corroborated clinical data, specific indicators, or parameters gauging the efficacy of this strategy for patients (10). Yang and colleagues conducted a study, involving 80 patients, examined bronchoscopic instillation of amphotericin B. The results showed 72.5% of patients experienced imaging improvements, 77.5% manifested imaging or localized containment of mycosis improvements, and 95% exhibited imaging improvements and containment or fell within the immunotherapy timeframe. This approach demonstrated a commendable success rate coupled with minimal adverse events, spotlighting its potential, particularly for systemic antifungal non-responders or those unable to tolerate it.Non-small-cell lung cancer (NSCLC) is one of the most common cancers worldwide and causes a vast number of cancer-related deaths (11). SMARCA4, a tumor suppressor gene, is reportedly mutated in approximately 10% of NSCLC patients and associated with poor prognosis (12).While immune checkpoint inhibitors have been used to treat NSCLC, immune-related adverse events can be challenging to manage and may limit the use of these therapeutic agents (13). In their report, Deng and co-workers shared their experiences regarding a patient with SMARCA4mutant NSCLC, who developed immune-related pneumonitis during anti-PD-1 treatment and chemotherapy. Switching therapies to corticosteroids and nintedanib, an anti-fibrotic multityrosine kinase inhibitor, led to the patient's recovery and allowed chemotherapy to resume. This study illustrates an interesting strategy of using an anti-fibrotic agent to manage immunerelated adverse events and encourages further research on the applications of nintedanib with immune checkpoint inhibitors in NSCLC.In summary, this special issue provides an exhaustive insight into the current state of research related to the diagnosis and management of respiratory diseases. It highlights pioneering therapeutic targets and the emergence of novel pharmaceutical agents in the field. This collection of studies underscores not only the depth of existing knowledge but also illuminates pathways toward new therapeutic strategies. Our aspiration is to catalyze further researches, particularly in translational applications, fostering the evolution of more refined and efficacious Strategies to improve patient outcomes in clinical practice.
NW drafted the manuscript with input from HT, JL and PY. All authors contributed to the article and approved the submitted version. FUNDING

